← Leaderboards
Jacalyn Rosenblatt
Beth Israel Deaconess Medical Center
$2,179,647
Attributed
$3,629,869
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $762.8K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,629,869 · 2
By mechanism
R01$2,900,444 · 1
R21$729,425 · 1
Top collaborators
- David E Avigan4 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- David E Avigan$5,917,131
- Keisuke Ito$9,818,052
- Mark L Andermann$16,810,308
- Ann A Kiessling$1,746,500
- Michael B Atkins$4,622,469
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaNeoplastic CellExhaustIn VivoMediatingMemoryDendritic CellsElementsGenerationsInvestigationLeukemic CellLigationAutologous Dendritic CellsClinical ResearchAntigensChemotherapyDisease RemissionEffector CellCellsCell FusionCharacteristicsImmuneAreaPathway Interactions
Grant awards (6)
Personalized Adoptive T-cell Therapy for AML$728,501
R01 · FY2025 · CA
Personalized Adoptive T-cell Therapy for AML$692,077
R01 · FY2024 · CA
Personalized Adoptive T-cell Therapy for AML$717,103
R01 · FY2022 · CA
Personalized Adoptive T-cell Therapy for AML$762,763
R01 · FY2021 · CA
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML$350,407
R21 · FY2011 · CA · contact PI
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML$379,018
R21 · FY2010 · CA · contact PI